MBX-8025 is an agonist of peroxisome proliferator-activated receptor δ (PPARδ).1 It is greater than 750- and 2,500-fold selective for PPARδ over PPARα and PPARγ. MBX-8025 (10 mg/kg per day for eight weeks) reduces increases in fasting blood glucose and serum insulin levels, and decreases insulin resistance in Alms1 mutant (foz/foz) mice fed an atherogenic diet as a model of diet-induced obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).2 It also decreases serum alanine transaminase (ALT), as well as serum and hepatic cholesterol and triglyceride, levels and reduces markers of NASH in the same model.
|1. Bays, H.E., Schwartz, S., Littlejohn, T., 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-δ agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 96(9), 2889-2897 (2011).|2. Haczeyni, F., Wang, H., Barn, V., et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol. Commun. 1(7), 663-674 (2017).
Gypenoside XIII (Standard) 是 Gypenoside XIII 的标准品。适用于定量分析、质量控制及生化实验等相关研究。Gypenoside XIII 是来源于 Gynostemma pentaphyllum 的绞股蓝皂苷,具有包括抗阿尔茨海默病、抗癌及抗动脉粥样硬化在内的多重药理作用,是一类具有广泛治疗潜力的多功能天然化合物,对神经退行性及系统性疾病具有研究意义。
Momordicosides K and L, the main bitter taste triterpene glycosides in Bitter melon; and bitter melon has been reported to have hypoglycemic, anti atherogenic and anti HIV activities.